A.M.L. is a healthcare practice in Antwerpen. Private Limited, started on 26 September 1984, 3 establishments.

What is the address of A.M.L.?

The registered office of A.M.L. is located at Emiel Vloorsstraat 9, 2020 Antwerpen.

Is A.M.L. still active?

Yes. According to the CBE (31 October 2026) A.M.L. is active, legal situation “Normale toestand”, started on 26 September 1984.

Is A.M.L. registered on Peppol?

Yes, A.M.L. is registered on the Peppol network with ID 0208:0426279168.

What is the enterprise number of A.M.L.?

The enterprise number of A.M.L. is BE0426279168.

When was A.M.L. founded?

A.M.L. was founded on 26 September 1984.

Who are the directors of A.M.L.?

According to the 2025 annual accounts, the directors of A.M.L. are: Koenraad Deweerdt.

Is A.M.L. a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 September 1984; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 3 establishments in the CBE.

How much profit did A.M.L. make in 2025?

A.M.L. posted a profit after taxes of € 10,903,163 in financial year 2025.

What is the revenue of A.M.L.?

In its most recent annual accounts (2025), A.M.L. reported revenue of € 54,249,587.

How much does an employee at A.M.L. earn?

The average wage cost per full-time employee at A.M.L. was € 69,100 in 2025: staff costs of € 19.7 million for 284.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does A.M.L. have?

According to the 2025 annual accounts, A.M.L. has 284.4 full-time equivalents (FTE).

A.M.L. (Private Limited) - Antwerpen - BE0426279168

Dossier A.M.L., printed on 31 October 2026 from databakkes.be/en/0426279168/a-m-l. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

A.M.L. from Antwerpen, company number BE0426279168, closed financial year 2025 with a result of € 10.9 million after tax. For that financial year A.M.L. recorded revenue of € 54.2 million and equity of € 62.8 million. Compared with financial year 2024, the result moved from € 10 million to € 10.9 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 13, 2026.

What it is worth Growing

€ 62.8 million

▲ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 10.9 million

▲ 9% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 6.3 million

▲ 13% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 10 million paid out

92 % of the profit went to the shareholders, mostly to KLINISCH LABO RIGO (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

284.4

▼ 2.9 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 15.7 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 19.7 million

€ 69,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 799,035

▲ 26% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 23.3 million

▲ 4% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 5.9 million

▼ 17% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 77 days on average.

Taxes and wages

€ 3.3 million

▼ 1% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 57,476,346 Revenue 2022: € 57,476,346 First fiscal year in the series	€ 54,813,648 Revenue 2023: € 54,813,648 ▼ 5% vs 2022 (€ 57,476,346) Unfavourable step	€ 51,939,140 Revenue 2024: € 51,939,140 ▼ 5% vs 2023 (€ 54,813,648) Unfavourable step	€ 54,249,587 Revenue 2025: € 54,249,587 ▲ 4% vs 2024 (€ 51,939,140) Favourable step	▲ 4%
Profit after taxes	€ 17,690,097 Profit after taxes 2022: € 17,690,097 First fiscal year in the series	€ 15,721,101 Profit after taxes 2023: € 15,721,101 ▼ 11% vs 2022 (€ 17,690,097) Unfavourable step	€ 9,994,544 Profit after taxes 2024: € 9,994,544 ▼ 36% vs 2023 (€ 15,721,101) Unfavourable step	€ 10,903,163 Profit after taxes 2025: € 10,903,163 ▲ 9% vs 2024 (€ 9,994,544) Favourable step	▲ 9%
Equity	€ 71,205,503 Equity 2022: € 71,205,503 First fiscal year in the series	€ 86,926,604 Equity 2023: € 86,926,604 ▲ 22% vs 2022 (€ 71,205,503) Favourable step	€ 61,921,148 Equity 2024: € 61,921,148 ▼ 29% vs 2023 (€ 86,926,604) Unfavourable step	€ 62,824,311 Equity 2025: € 62,824,311 ▲ 1% vs 2024 (€ 61,921,148) Favourable step	▲ 1%
Total debts	€ 50,809,193 Total debts 2022: € 50,809,193 First fiscal year in the series	€ 43,241,236 Total debts 2023: € 43,241,236 ▼ 15% vs 2022 (€ 50,809,193) Favourable step	€ 41,328,235 Total debts 2024: € 41,328,235 ▼ 4% vs 2023 (€ 43,241,236) Favourable step	€ 42,108,085 Total debts 2025: € 42,108,085 ▲ 2% vs 2024 (€ 41,328,235) Unfavourable step	▲ 2%
Cash	€ 17,593,168 Cash 2022: € 17,593,168 First fiscal year in the series	€ 9,484,316 Cash 2023: € 9,484,316 ▼ 46% vs 2022 (€ 17,593,168) Unfavourable step	€ 5,580,111 Cash 2024: € 5,580,111 ▼ 41% vs 2023 (€ 9,484,316) Unfavourable step	€ 6,320,780 Cash 2025: € 6,320,780 ▲ 13% vs 2024 (€ 5,580,111) Favourable step	▲ 13%
Retained profit	€ 22,748,816 Retained profit 2022: € 22,748,816 First fiscal year in the series	€ 38,469,917 Retained profit 2023: € 38,469,917 ▲ 69% vs 2022 (€ 22,748,816) Favourable step	€ 13,464,461 Retained profit 2024: € 13,464,461 ▼ 65% vs 2023 (€ 38,469,917) Unfavourable step	€ 14,367,624 Retained profit 2025: € 14,367,624 ▲ 7% vs 2024 (€ 13,464,461) Favourable step	▲ 7%
Dividend	€ 23,000,000 Dividend 2022: € 23,000,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 23,000,000) Unchanged	€ 35,000,000 Dividend 2024: € 35,000,000 Unchanged (€ 0) Unchanged	€ 10,000,000 Dividend 2025: € 10,000,000 ▼ 71% vs 2024 (€ 35,000,000) Unchanged	▼ 71%
Bank debt	€ 20,657,133 Bank debt 2022: € 20,657,133 First fiscal year in the series	€ 21,461,148 Bank debt 2023: € 21,461,148 ▲ 4% vs 2022 (€ 20,657,133) Unfavourable step	€ 22,492,894 Bank debt 2024: € 22,492,894 ▲ 5% vs 2023 (€ 21,461,148) Unfavourable step	€ 23,338,328 Bank debt 2025: € 23,338,328 ▲ 4% vs 2024 (€ 22,492,894) Unfavourable step	▲ 4%
Balance sheet total	€ 122,014,696 Balance sheet total 2022: € 122,014,696 First fiscal year in the series	€ 130,167,840 Balance sheet total 2023: € 130,167,840 ▲ 7% vs 2022 (€ 122,014,696) Unchanged	€ 103,249,383 Balance sheet total 2024: € 103,249,383 ▼ 21% vs 2023 (€ 130,167,840) Unchanged	€ 104,932,396 Balance sheet total 2025: € 104,932,396 ▲ 2% vs 2024 (€ 103,249,383) Unchanged	▲ 2%
Employees (FTE)	294.8 Employees (FTE) 2022: 294.8 First fiscal year in the series	290.8 Employees (FTE) 2023: 290.8 ▼ 4 vs 2022 (294.8) Unchanged	287.3 Employees (FTE) 2024: 287.3 ▼ 3.5 vs 2023 (290.8) Unchanged	284.4 Employees (FTE) 2025: 284.4 ▼ 2.9 vs 2024 (287.3) Unchanged	▼ 2.9

Key figures of A.M.L., fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to A.M.L.?

What happened at A.M.L. in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 13, 2026 New annual accounts for financial year 2025: profit of € 10.9 million (▲ 9% vs 2024). Source: NBB ↗
2024 Koenraad Deweerdt became a director. NBB
Dec 11, 2018 New establishment in Lokeren. KBO
May 22, 2015 New establishment in Sint-Pieters-Woluwe. KBO
Jul 20, 1997 New establishment in Antwerpen. KBO
Sep 26, 1984 Start of the company according to the CBE. KBO

In short

From € 17.7 million profit in 2022 to € 10.9 million profit in 2025.

Paid € 5.1 million in corporate taxes since 2022.

Best year ever: 2022, with € 17.7 million profit.

Paid out € 68 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

KLINISCH LABO RIGO 100%

The stake of KLINISCH LABO RIGO comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

A.M.L.

AML West 100%

Medvet 100%

Behind A.M.L. is Koenraad Deweerdt. The shares are held by KLINISCH LABO RIGO (100%). It owns 100% of AML West and 100% of Medvet itself.

Directors

According to the 2025 annual accounts

Koenraad Deweerdt

Director

Also active at: SONIC HEALTHCARE BENELUX

since 2024

Shareholders

KLINISCH LABO RIGO

100%

Participations

AML West

100%

Medvet

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Emiel Vloorsstraat 9

2020 Antwerpen

2.241.359.105

Meiersplein 2

1150 Sint-Pieters-Woluwe

Active since 22 May 2015

2.282.989.426

Oude-Bruglaan 72 box 2

9160 Lokeren

Active since 11 December 2018

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

MEDVET same network

€ 7.7 million revenue · 2025

SONIC HEALTHCARE BENELUX same network

€ 540,919 revenue · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0426.279.168

VAT number

BE 0426.279.168

Registered office

Emiel Vloorsstraat 9, 2020 Antwerpen

Names & denominations

A.M.L.

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

26 September 1984

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Activiteiten van medische beeldvorming en medische laboratoria

Medische laboratoria

Activiteiten van medische laboratoria

View on CBE Public ↗ Annual accounts (NBB) ↗

A.M.L.

Financials

What happened to A.M.L.?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions